

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application : Dana M. Fowlkes et al.
Serial No. : 09/050,359
Filed : March 31, 1998
For : IDENTIFICATION OF DRUGS USING
COMPLEMENTARY COMBINATORY LIBRARIES
Examiner : Wessendorf, Teresa
Attorney Docket : 102553-200
Group Art Unit : 1639
Confirmation No. : 6741
Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on _____.

By _____
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

[] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

[X] 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

[] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).

[] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).

[X] Please charge Deposit Account No. 23-1665 in the amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.

[] A check in the amount of \$180.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).

[] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.

[] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

[] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

[] Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.

[] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,


DANA M. FOWLKES, ET AL.

Date: 17 FEB 2005

By: Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508-1832

Telephone : (203) 498-4400
Telecopier: (203) 782-2889



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Dana M. Fowlkes et al.
Serial No. : 09/050,359
Filed : March 31, 1998
For : IDENTIFICATION OF DRUGS USING
COMPLEMENTARY COMBINATORY LIBRARIES
Examiner : Wessendorf, Teresa
Attorney Docket : 102553-200
Group Art Unit : 1639
Confirmation No. : 6741
Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 17 FEB 2005.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE LETTER

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

1. HOUGHTEN, RICHARD A., ET AL., "*Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery*", Nature, Vol. 354, Pages 84-86, 7 November 1991 (1991-11-7).

Applicants submit that a copy of the above-cited reference is enclosed herewith.

If the Examiner has any questions or feels that a discussion with Applicants' representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

DANA M. FOWLKES, ET AL.

Date: 17 FEB 2005

By: Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN AND DANA LLP
One Century Tower
P. O. Box 1832
New Haven, CT 06508-1832
Telephone: (203) 498-4400
Fax: (203) 782-2889

\12868\1\516374.1

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>RECEIVED FEB 22 2005 U.S. PATENT AND TRADEMARK OFFICE</i>		ATTY. DOCKET NO. 102553-200		SERIAL NO. 09/050,359	
		APPLICANT: DANA M. FOWLKES, ET AL.		FILING DATE: MARCH 31, 1998 GROUP: 1639	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS
					TRANSLATION Yes No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					
	HOUGHTEN, RICHARD A., ET AL., " <i>Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery</i> ", Nature, Vol. 354, Pages 84-86, 7 November 1991 (1991-11-7).				
EXAMINER:			DATE CONSIDERED:		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p>\12868\11\516376.1</p>					